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Amine-containing buffers produce anomalous results
With Tris or HEPES buffers, experiments on puriﬁed iNicSnFRs gave elevated F0 values and decreased ΔF values, compared with
phosphate buffers. Isothermal titration calorimetry experiments with Tris buffers gave afﬁnities much lower than with phosphate-
containing buffers. We found similar anomalies with MOPS at >10 mM.
In experiments on puriﬁed iNicSnFR proteins, like those of Fig. 3, MOPS buffer at ≤10 mM produced minimal perturbation.
However, live-cell experiments with MOPS and iNicSnFR3a_ER gave anomalously low ΔF/ F0, probably because this buffer allowed
the ER to become acidic.
Use of HEPES might have degraded the quality of the crystallographic data showing nicotine at the binding site. Even slight
afﬁnity to the buffer molecule might produce competition with the desired ligand. Examples of crystallized protein containing the
amine buffer, rather than nicotine, ACh, or choline, are provided by the studies of ACh-binding protein (Brejc et al., 2001; PDB ﬁle
1I9B) and of ProX (Tschapek et al., 2011; PDB ﬁle 3MAM).
Acidic vesicles as candidates for the “sequestered compartment”
Our simulations include a “sequestered” compartment. This was previously termed a “peripheral” compartment (Benowitz et al.,
1991), but the previous terminology would introduce confusion about nicotine in the peripheral nervous system. Wording aside,
where is this sequestered compartment, whose chief characteristic is that it remains inaccessible frommetabolic enzymes? Early on,
it was pointed out (de Duve et al., 1974) that weak bases accumulate, perhaps by factors of 100, in lysosomes or other acidic
compartments. In 2009, it was suggested that nicotine could also become concentrated in this fashion (Lester et al., 2009). The
pharmacokinetic literature points out that lysosomes (pH ∼4.5), representing just ∼1% of a cell’s volume, but concentrating a weakly
basic drug by ∼100-fold, could accumulate as much drug as the entire cellular and extracellular compartments (Smith et al., 2012).
Tischbirek et al. (2012) provided experimental evidence that antipsychotic drugs, which are also weak bases, accumulate in synaptic
vesicles (pH ∼5.5) and also presented a quantitative analysis including the dependence on logD and membrane permeation of the
protonated, charged form (Trapp et al., 2008; Tischbirek et al., 2012). These concepts strengthen the recent suggestion that vare-
nicline accumulates in lysosomes (Govind et al., 2017).
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Figure S1. Sequences of PBPs and constructs described in this paper and/or studied in preliminary experiments. The nicotine dose–response char-
acteristics of iNicSnFR1 and iNicSnFR2 biosensors are given in Fig. S2 B. These constructs have not been studied systematically in mammalian cells with
optimized methods. Experiments with iAChSnFR are described elsewhere (Borden et al., in preparation). Important domains are noted on the sequences. Based
on a SwissDock simulation of nicotine in iNicSnFR1 (see Fig. 2 B), we have annotated the seven aromatic residues within 5 A˚ of the pyrrolidine nitrogen in
nicotine. These are labeled α through η. One or more of these side chains may be involved in a cation-π interaction with the protonated pyrrolidine moiety of
nicotine, with the quaternary amine of N’MeNic, and/or with the secondary amine of varenicline (Tavares et al., 2012; Post et al., 2017). The OpuBC sequence is
annotated with a gray background at the 25 codons we subjected to SSM experiments. In communications among the collaborators on this project, we have
used the following additional descriptions and temporary names. For iNicSNFR1: CC47, V4.6. For iNicSNFR2: CC90. For iNicSnFR3a: CC93. For iN-
icSnFR3a_Y357A_PM: CC105. For iNicSnFR3b: V7. For iAChSnFR: V9.
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Figure S2. Directed evolution of the iNicSnFR family. (A) A history of our progress toward the goal of ΔF/F0 > 0.3 at 1 µM nicotine. Initial experiments used
ChoX, a choline PBP from Sinorhizobium meliloti. However, these constructs responded to ligands in solution with a time constant of τ > 100 s and were also
poorly expressed in mammalian cells. We ceased systematic development of ChoX-based constructs. Later experiments used OpuBC from T. spX513, as
described in the text and in Fig. 2. The reported values were measured in Escherichia coli cell lysates; values for key constructs were later veriﬁed with samples
of the puriﬁed proteins. (B) Final stages in protein engineering of iNicSnFR constructs. For constructs denoted by black or white symbols, ΔF/F0 at >1 µM
nicotine was extrapolated from measurements on bacterial lysates as [ΔF/Fmax]/EC50. For constructs denoted by green symbols, ΔF/F0 at 0.3 µM nicotine was
measured directly on bacterial lysates. The designs of the mutant libraries were based on the iNicSnFR1 structure depicted in Fig. 2 A and the docking results of
Fig. 2 B. The sites selected for mutagenesis include the nicotine-binding pocket, linker residues, and the interface between OpuBC and cpGFP. Interestingly, the
substitution A360T improved afﬁnity despite its location “far” from the binding pocket (on a β-sheet next to one of the active site loops). The site A360 was
selected based on the crystal structure of ACh-binding protein (AChBP) in complex with nicotine (PDB ﬁle 1UW6). Additional names for communications among
collaborators are given in Fig. S1. Red: binding site substitution. Techniques: site saturation mutagenesis (several rounds), site-directed mutagenesis, and
multisite-directed mutagenesis.
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Figure S3. Photoswitching (bleaching) is noticeable at high [nicotine] with focused laser illumination. (A) Photoswitching (bleaching) increases at the
highest illumination intensities and at higher [nicotine]. HeLa cells transfected with iNicSnFR3a_PM. Imaging at 1 and 30 µM nicotine, with 100% and 10% laser
intensity (top and bottom, respectively). At 30 µM nicotine, photoswitching reduced the steady-state ΔF to 45 versus 71% of the peak ΔF for 100% and 10%
laser intensity, respectively. The steady-state ratio, ΔF(30 µM) to ΔF(1 µM) was 4.92 versus 11.2 for 100% and 10%, respectively, indicating that high intensities
artifactually shifted the dose–response relation ([nicotine] vs. ΔF) to lower [nicotine]. Traces are mean ± SEM; three cells. At 30 µM nicotine, photoswitching
also proceeded more rapidly for 100% than for 10% intensity (time constant, 3.47 vs. 5.55 s, respectively). At 1 µM nicotine, data were too noisy for systematic
kinetic studies. (B) Photoswitching is reversible. HeLa cells transfected with iNicSnFR3a_PM, imaging at 30 µM nicotine. During an initial 20-s nicotine ap-
plication, ΔF reaches a peak, then decreases. During a second 200-s application, ΔF reaches a peak, then recovers to a plateau. The laser is switched off for 60 s
during the continued presence of nicotine. When the laser is switched on again, ΔF appears to have recovered to its initial peak, then bleaches to its former
plateau. Traces are normalized from ﬁve cells, and the gray bands show ± SEM. (C) Further analysis of reversible photoswitching. HeLa cells transfected with
iNicSnFR3a_ER. Experiment at 100% laser intensity, 30 µM versus 3 µM nicotine. When 30 µM nicotine is removed, the trace reveals a transient decrease in F0
(red arrow). In the absence of nicotine, when iNicSnFR is absorbing fewer photons, F0 recovers to its unbleached state over the next 10 s. Photoswitching was
not observed with LED illumination.
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Figure S4. Responses to nicotine with iNicSnFR_ER in SH-SY5Y cells and HEK293 cells. (A and B) iNicSnFR_ER was transfected and imaged in SH-SY5Y
(A) and HEK293 cells (B). Nicotine pulses were applied for 20 s at 40-s intervals. The nicotine concentration was stepped from 256 µM to 250 nM and then from
250 nM to 256 µM in 4× concentration steps in HBSS. The mean of three cells is given as a solid black line, and the SEM is given as gray bounds.
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Figure S5. Human iPSCs, differentiated to dopaminergic neurons, transduced with AAV_iNicSnFR3b_ER. This ﬁgure accompanies the video of a de-
scending, then ascending, series of nicotine concentrations at ﬁvefold steps between 0.2 and 125 µM. Concentrations and washes (“0 µM”) are marked on the
video. (A) The image shows a single frame taken at 25 µM nicotine, indicating three cells (dim, moderate, and bright). (B) Plots of the average absolute intensity
of these images (log scale), without correction for sloping baseline or conversion to ΔF/F0. Note that in the descending phase, the responses begin more quickly
and, at the lower [nicotine], show an initial transient. This is an artifactual result when solutions in a pH-regulated reservoir are allowed to remain in gas-
permeable intermediate tubing, allowing CO2 to escape and rendering the solutions slightly more basic (see Materials and methods). The second application of
each solution utilizes solution that has recently moved from the larger reservoir; the transients no longer appear.
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Figure S6. Varenicline at iNicSnFR3a expressed in HeLa cells. (A and C) Dose–response relations for varenicline-induced ΔF/F0. Mean ± SEM; three
measurements. (B and D) Dose–response plots for ΔF/F0 at each response in A and C, against [varenicline]. Single-component Hill equation ﬁt, including zero
response at zero [varenicline]. Parameter values are shown.
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Table S1. Structure and reﬁnement of iNicSnFR1 crystallized with nicotine
Wavelength, A˚ 1.541
Resolution range, A˚ 61.64–2.4 (2.486–2.4)
Space group I 2 2 2
Unit cell, A˚ 80.61, 95.64, 151.79, 90, 90, 90
Total reﬂections 758,695 (72898)
Unique reﬂections 23,162 (2253)
Multiplicity 32.8 (32.3)
Completeness, % 99.07 (98.82)
Mean I/σ(I) 47.79 (3.74)
Wilson B-factor 36.67
Rmerge 0.749 (1.909)
Rmeas 0.761 (1.939)
Rpim 0.133 (0.342)
CC1/2 0.924 (0.737)
CC* 0.98 (0.921)
Reﬂections used in reﬁnement 23,132 (2253)
Reﬂections used for R-free 1178 (100)
Rwork 0.1902 (0.2311)
Rfree 0.2521 (0.3714)
CCwork 0.878 (0.811)
CCfree 0.828 (0.381)
Number of non-hydrogen atoms 4,042
macromolecules 3,989
ligands 22
solvent 31
Protein residues 504
RMS deviation, bonds 0.009
RMS deviation angles 1.36
Ramachandran plot: favored % 95.56
Allowed % 4.44
Outliers % 0.00
Rotamer outliers % 0.23
Clash score 10.25
Average B-factor 45.07
macromolecules 45.17
ligands 29.03
solvent 42.60
Number of TLS groups 4
Statistics for the highest-resolution shell are shown in parentheses.
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Table S3. Supplemental videos
Cell type Drug MP4 ﬁle
number
Expression construct, LED voltage,
Concentrations (if not labelled in the video)
Total
time, s
Drug
additions, s
Speed vs real
time (fold)
iDopaNeurons
(iPSCs)
Nicotine 1 AAV2-iNicSnFR3b_ER, 17days, 120mV,
125-25-5-1-0.2 µM
193 20 5.9
HeLa cells Nicotine 2 iNicSnFR3a_PM, 30mV 285 20 9.5
3 iNicSnFR_ER,30mV 289 20 9.6
Varenicline 4 iNicSnFR3a, PM, 30mV 401 30 12.9
5 iNicSnFR3a_ER, 30mV 396 30 13.2
Hippocampal
Cultures
Nicotine 6 AAV2-iNicSnFR3b_ER, 62mV 342 20 12.2
7 AAV2-iNicSnFR3b_PM, 125mV 335 20 12
Varenicline 8 AAV2-iNicSnFRb_PM, 180mV 569 20 16.7
9 AAV2-iNicSnFR3b_ER, 16mV 564 20 17.1
Each video is colored using the “ﬁre” lookup table (blue < red < white). The lookup table is constant across the ﬁeld and within each video, so that cells with
varying levels of iNicSnFRs begin with varying colors. The general procedure is a series of steps in concentration of a single drug (either nicotine or varenicline),
separated by control solution. Field of view is 211-µM wide. Please begin with Video 1 (nicotine). Its annotation is most complete, and it shows a
“descending-increasing” series of nicotine concentrations. Figure S5 is a frame from this movie.
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